A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer

Breast Cancer Research and Treatment, 05/08/2012

The tipifarnib–capecitabine combination is not more effective than capecitabine alone in metastatic breast cancer (MBC) patients who were previously treated with an anthracycline and taxane therapy.

Print Article Summary Cat 2 CME Report